Veradermics (MANE) insiders disclose indirect stakes in common stock

Rhea-AI Filing Summary

Suvretta Capital Management, LLC and affiliated reporting persons disclosed their initial insider holdings in Veradermics, Inc. common stock. As of February 4, 2026, they indirectly beneficially owned 3,515,458 shares of common stock and an additional 370,859 shares, both reported as indirect ownership.

The filing is an initial statement of beneficial ownership, not a report of new share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider SUVRETTA CAPITAL MANAGEMENT, LLC, Cowen Aaron, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.

Role Director, 10% Owner | 10% Owner | Director, 10% Owner | Director, 10% Owner

Type	Security	Shares	Price	Value
holding	Common stock, par value $0.00001 per share	--	--	--
holding	Common stock, par value $0.00001 per share	--	--	--

Holdings After Transaction: Common stock, par value $0.00001 per share — 3,515,458 shares (Indirect, I)

Footnotes (1)

1. Notes are included on Exhibit 99.1 hereto. Notes are included on Exhibit 99.1 hereto. Notes are included on Exhibit 99.1 hereto. Notes are included on Exhibit 99.1 hereto.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SUVRETTA CAPITAL MANAGEMENT, LLC

(Last) (First) (Middle)

540 MADISON AVENUE

7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/04/2026

3. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, par value $0.00001 per share	3,515,458(1)(2)	I(4)	I(4)
Common stock, par value $0.00001 per share	370,859(1)(3)	I(4)	I(4)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SUVRETTA CAPITAL MANAGEMENT, LLC

(Last) (First) (Middle)

540 MADISON AVENUE

7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Cowen Aaron

(Last) (First) (Middle)

C/O SUVRETTA CAPITAL MANAGEMENT, LLC

540 MADISON AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Averill Master Fund, Ltd.

(Last) (First) (Middle)

C/O SUVRETTA CAPITAL MANAGEMENT, LLC

540 MADISON AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Averill Madison Master Fund, Ltd.

(Last) (First) (Middle)

C/O SUVRETTA CAPITAL MANAGEMENT, LLC

540 MADISON AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Notes are included on Exhibit 99.1 hereto.

2. Notes are included on Exhibit 99.1 hereto.

3. Notes are included on Exhibit 99.1 hereto.

4. Notes are included on Exhibit 99.1 hereto.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signatures

	Suvretta Capital Management, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Veradermics (MANE) disclose in this Form 3 filing?

The filing discloses initial insider holdings of Veradermics common stock. Reporting persons associated with Suvretta Capital Management, LLC report indirect beneficial ownership of two blocks of MANE shares, establishing their status as significant shareholders and Section 16 reporting persons.

How many Veradermics (MANE) shares are indirectly owned according to the Form 3?

The Form 3 reports indirect beneficial ownership of 3,515,458 shares of Veradermics common stock and a further 370,859 shares. Both positions are listed as indirectly held, reflecting holdings through related entities rather than direct personal ownership of the reporting persons.

Who are the reporting persons in the Veradermics (MANE) Form 3?

Reporting persons include Suvretta Capital Management, LLC, Aaron Cowen, Averill Master Fund, Ltd., and Averill Madison Master Fund, Ltd. The filing marks several of them as directors and 10% owners, indicating significant share ownership and governance roles at Veradermics.

Does this Veradermics (MANE) Form 3 reflect any insider buying or selling?

The Form 3 functions as an initial statement of beneficial ownership and does not specify any buy or sell transactions. The transactions are coded as holdings, with total shares reported after the event date rather than changes from earlier reported positions.

What is the event date for the Veradermics (MANE) insider holdings reported?

The event date for the reported beneficial ownership is February 4, 2026. As of that date, the reporting persons collectively disclose indirect positions in Veradermics common stock, triggering their initial Section 16 reporting obligations through this Form 3.

How is the ownership of Veradermics (MANE) shares characterized in this Form 3?

Both reported Veradermics common stock positions are characterized as indirect ownership. The tables mark the holdings with an “I” code, and footnote references direct readers to Exhibit 99.1 for detailed explanations of the indirect beneficial ownership structure.